References
- Yangyang RY, Rodriguez JR, editors. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Seminars in pediatric surgery; 2017: Elsevier.
- Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am. 2020;49(4):671-88. DOI: 10.1016/j.gtc.2020.08.003
- Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease. Digestion. 2023;104(1):30-41. DOI: 10.1159/000527846
- Sagawa T, Kakizaki S, Tomizawa T, Nakayama T, Tanaka H, Tojima H, et al. Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy. Colorectal Dis. 2016;18(7):696-702. DOI: 10.1111/codi.13258
- Truelove SC, Witts L. Cortisone in ulcerative colitis. British medical journal. 1955;2(4947):1041. DOI: 10.1136/bmj.2.4947.1041
- Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun rev. 2014;13(4-5):463-6. DOI: 10.1016/j.autrev.2014.01.028
- Laass MW, Ziesmann J, de Laffolie J, Röber N, Conrad K. Anti-Proteinase 3 Antibodies as a Biomarker for Ulcerative Colitis and Primary Sclerosing Cholangitis in Children. J Pediatr Gastroenterol Nutr. 2022 Apr 1;74(4):463-470. DOI: 10.1097/MPG.0000000000003359
- Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. New England J Med. 1987;317(26):1625-9. DOI: 10.1056/NEJM198712243172603
- Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992 Aug;87(8):971-6.
- Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008;14(1):53-7. DOI: 10.3748/wjg.14.53
- Grgić D, Golubić K, Brinar M, Krznarić Ž. Predictive value of faecal calprotectin in ulcerative colitis - single centre experience. Ann Med. 2022;54(1):1570-7. DOI: 10.1080/07853890.2022.2082518
- Acharya K, Bhardwaj V, Chuahan I, Mushfiq S, Bhatt S, Lamba BM. Comparison of Fecal Calprotectin with Different Endoscopic Scores in the Assessment of Ulcerative Colitis (UC) Activity and Its Utility in Differentiating IBS from IBD. Euroasian J Hepatogastroenterol. 2023;13(2):120-3. DOI: 10.5005/jp-journals-10018-1411
- Vieira A, Fang CB, Rolim EG, Klug WA, Steinwurz F, Rossini LGB, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC res notes. 2009;2:1-7. DOI: 10.1186/1756-0500-2-221
- Jones J, Loftus Jr EV, Panaccione R, Chen LS, Peterson S, Mcconnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2008 Nov;6(11):1218-24. DOI: 10.1016/j.cgh.2008.06.010
- Sipponen T, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, Färkkilä M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008 Jan;14(1):40-6. DOI: 10.1002/ibd.20312
- Langhorst J, Kairey L, Oberle A, Boone J, Dobos G, Juette H, et al. Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin. Crohns Colitis 360. 2020;2(3):otaa053. DOI: 10.1093/crocol/otaa053
- Dai C, Jiang M, Sun M-J, Cao Q. Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2020;54(6). DOI: 10.1097/MCG.0000000000001212
- Moiseev S, Cohen Tervaert JW, Arimura Y, Bogdanos DP, Csernok E, Damoiseaux J, et al. 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev. 2020;19(9):102618. DOI: 10.1016/j.autrev.2020.102618
- Reumaux D, Colombel J-F, Masy E, Duclos B, Heresbach D, Belaïche J, et al. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflamm Bowel Dis. 2000 Nov;6(4):270-4. DOI: 10.1002/ibd.3780060403
- Høie O, Aamodt G, Vermeire S, Bernklev T, Odes S, Wolters FL, et al. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. J Crohns Colitis. 2008;2(2):114-22. DOI: 10.1016/j.crohns.2007.10.001
- Roozendaal C, Pogany K, Hummel E, Horst G, Dijkstra G, Nelis G, et al. Titres of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. QJM. 1999;92(11):651-8. DOI: 10.1093/qjmed/92.11.651